Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching,Pain,and Scaling than Placebo and Etanercept

Abstract

Background

Secukinumab, a fully human anti-interleukin 17A monoclonal antibody, has demonstrated rapid, strong, and sustained efficacy in moderate-to-severe plaque psoriasis.

Objective

To measure treatment effect on psoriasis-related itching, pain, and scaling during the first 12 weeks of treatment.

Methods

ERASURE and FIXTURE were double-blind, multicenter, phase 3 studies in adults randomly assigned to secukinumab (300 mg or 150 mg), placebo, or etanercept (FIXTURE only). Improvements in itching, pain, and scaling and their bothersomeness, proportions of responders and proportions reporting complete symptom relief were compared.

Results

Subjects treated with secukinumab reported significantly greater symptom improvement versus etanercept and placebo as well as bothersomeness reduction (all P < 0.01). The proportion of symptom responders and proportions reporting complete relief favored secukinumab.

Limitations

Approximately 39% of patients provided data on psoriasis-related itching, pain, and scaling.

Conclusions

Secukinumab significantly improves patient-reported itching, pain, and scaling compared with etanercept and placebo over 12-week psoriasis treatment.

Keywords

psoriasis secukinumab patient-reported outcome itching pain scaling bothersomeness Psoriasis Symptom Diary

Get full access to this article

View all access options for this article.

References

Van Voorhees

Feldman

S.R.

Koo

The psoriasis and psoriatic arthritis pocket guide. 2009. Available at: http://psoriasis.org/health-care-providers/treating-psoriasis. Accessed 4 May 2015.

de Korte

Sprangers

M.A.

Mombers

F.M.

Bos

J.D.

. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004; 9: 140–147.

Lebwohl

M.G.

Bachelez

Barker

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

J Am Acad Dermatol. 2014 May; 70(5): 871–881.

Lebwohl

Swensen

A.R.

Nyirady

The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument.

Int J Dermatol. 2014 Jun; 53(6): 714–722.

Martin

M.L.

McCarrier

K.P.

Chiou

C.F.

Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity

J Dermatolog Treat. 2013 Aug; 24(4): 255–260.

Mrowietz

Kragballe

Reich

Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Arch Dermatol Res. 2011 Jan; 303(1): 1–10.

Raval

Lofland

J.H.

Waters

Piech

C.T.

. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol. 2011 Feb; 10(2): 189–196.

Sterry

Barker

Boehncke

W.H.

Biological therapies in the systemic management of psoriasis: international consensus conference.

Br J Dermatol. 2004: 151(Suppl. 69): 3–17.

Novartis Pharma

A.G.

. Consentyx prescribing information. 2015. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf. Accessed 23 February 2015.

10.

Langley

R.G.

Elewski

B.E.

Lebwohl

Secukinumab in Plaque Psoriasis: Results of Two Phase 3 Trials.

N Engl J Med. 2014 Jul 24;371(4): 326–338.

11.

Strober

Gottlieb

A.B.

Elewski

Item-level psychometric properties for a new patient-reported symptom diary.

Value Health. 2013; 16: 1014–1022.

12.

Food and Drug Administration (FDA). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 4 May 2015.